Patents by Inventor Durga Maheswari Parvataneni

Durga Maheswari Parvataneni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions comprising phenylaminopyrimidine derivative
    Patent number: 10383872
    Abstract: An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs thereof, by dispersing in a polymer system in a final state of subdivision to enhance oral bioavailability. It also relates to processes for the preparation of such compositions and using those compositions for the treatment of Chronic Myeloid Leukemia and other tumors such as head and neck cancer, prostate cancer and the like.
    Type: Grant
    Filed: January 30, 2016
    Date of Patent: August 20, 2019
    Assignee: NATCO PHARMA LTD
    Inventors: Durga Maheswari Parvataneni, Mitrabhanu Mohanty, Venkata Satyanarayana Appadwedula, Kali Satya Bhujanga Rao Adibhatla, Venkaiah Chowdary Nannapaneni
  • Pharmaceutical compositions comprising phenylaminopyrimidine derivative
    Patent number: 10350209
    Abstract: An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs thereof, by dispersing in a polymer system in a final state of subdivision to enhance oral bioavailability. It also relates to processes for the preparation of such compositions and using those compositions for the treatment of Chronic Myeloid Leukemia and other tumors such as head and neck cancer, prostate cancer and the like.
    Type: Grant
    Filed: January 30, 2016
    Date of Patent: July 16, 2019
    Assignee: NATCO PHARMA LTD
    Inventors: Durga Maheswari Parvataneni, Mitrabhanu Mohanty, Venkata Satyanarayana Appadwedula, Kali Satya Bhujanga Rao Adibhatla, Venkaiah Chowdary Nannapaneni
  • PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE
    Publication number: 20190015412
    Abstract: An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs thereof, by dispersing in a polymer system in a final state of subdivision to enhance oral bioavailability. It also relates to processes for the preparation of such compositions and using those compositions for the treatment of Chronic Myeloid Leukemia and other tumors such as head and neck cancer, prostate cancer and the like.
    Type: Application
    Filed: January 30, 2016
    Publication date: January 17, 2019
    Inventors: Durga Maheswari PARVATANENI, Mitrabhanu MOHANTY, Venkata Satyanarayana APPADWEDULA, Kali Satya Bhujanga Rao ADIBHATLA, Venkaiah Chowdary NANNAPANENI
  • Formulation comprising phenylaminopyrimidine derivative as active agent
    Patent number: 9895367
    Abstract: An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: February 20, 2018
    Assignee: NATCO PHARMA LIMITED
    Inventors: Durga Maheswari Parvataneni, Siddhartha Yedluri, Venkata Satyanarayana Appadwedula, Kali Satya Bhujanga Rao, Venkaiah Chowdary Nannapaneni
  • FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT
    Publication number: 20130338180
    Abstract: An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like.
    Type: Application
    Filed: August 10, 2011
    Publication date: December 19, 2013
    Applicant: NATCO PHARMA LIMITED
    Inventors: Durga Maheswari Parvataneni, Siddhartha Yedluri, Venkata Satyanarayana Appadwedula, Kali Satya Bhujanga Rao, Venkaiah Chowdary Nannapaneni